Gallium-68 Market is expected to reach US$ 1,070.34 million by 2030

Oncology Application to Hold Significant Share of Gallium-68 Market During 2022–2030

According to our latest study on "Gallium-68 Market Forecast to 2030 – Global Analysis – Application and End User," the market value is expected to reach US$ 1,070.34 million by 2030 from US$ 782.36 million in 2022 at a CAGR of 4.0%. The report emphasizes the key factors driving the market and prominent players' developments. Factors such as an increase in the prevalence of prostate cancer and neuroendocrine tumors, and an upsurge in the use of nuclear imaging techniques propel the market growth. However, the short half-life of gallium-68 impedes the market growth. Further, the use of radioactive tracers in cancer diagnosis is expected to bring new gallium-68 market trends in the coming years.

Advanced radiation technology has opened new horizons in diagnostic and nuclear medicine, radiotherapy, and interventional radiology. The application of ionizing radiation in diagnoses and treatments benefits millions of patients globally. Positron emission tomography (PET) is a commonly used radiology modality in clinical settings, as it aids in the accurate detection, localization, and characterization of diseases. According to the World Health Organization (WHO), more than 3.6 billion radiology-based diagnostic examinations, 37 million nuclear medicine procedures, and 7.5 million radiotherapy treatments are performed annually worldwide. As per the European Commission, ~10 million nuclear medicine procedures are performed with radiopharmaceuticals and imaging instruments every year in Europe to diagnose diseases and deliver targeted treatments. These techniques are also adopted in oncology, immunology, infection studies, gastroenterology, cardiology, neurology, and psychiatry. The development and introduction of new radiopharmaceuticals for PET/CT contribute to the gallium-68 market growth. Moreover, the increased accuracy provided by gallium-18 in different tumor staging methods propels its demand in radiology applications. For instance, newly introduced prostate imaging radiopharmaceuticals such as Ga-68 gozetotide help in more precise prostate cancer imaging.

Gallium-68 Market, by Geography, 2022 (%)

To get sample Copy of the report, along with the TOC, Statistics, and Tables please visit @ https://www.theinsightpartners.com/brochure/TIPRE00029992

Source: The Insight Partners Analysis

The shelf-life of radiopharmaceuticals depends mainly on the half-life and radiochemical stability of radioisotopes, and the radionuclide impurity content in the preparation. Most radiopharmaceutical preparations contain radioisotopes with very short half-lives. For example, Gallium-68 must be used within 68 minutes of preparation. The shelf-life of a multidose radiopharmaceutical preparation after aseptic withdrawal of the first dose depends on microbiological considerations. In case of a short half-life of radionuclides, the diagnostic radiopharmaceuticals are usually prepared in the hospital radiopharmacy departments just before the administration to patients. The half-life of gallium-68 is 68 minutes, which is considerably less than the half-life of other radiopharmaceuticals such as fluorine-18 (109.8 minutes) and technetium-99m (6 hours). Therefore, the short life of radiopharmaceuticals is becoming a matter of concern in long-term procedures, which is a major factor restraining the gallium-68 market growth.

The “gallium-68 market analysis” has been carried out by considering the following segments: application and end user. By application, the market is segmented into oncology, neurology, cardiology, and others. The oncology segment held the largest market share in 2022, and it is anticipated to register the highest CAGR during the forecast period. The gallium-68 market for the oncology segment is subsegmented into prostate cancer, neuroendocrine tumors, and others. The market, by end user, is categorized into hospitals, diagnostic and imaging centers, and others. The hospitals segment held the largest gallium-68 market share in 2022. It is further anticipated to register the highest CAGR during the forecast period.

Gallium-68 Market, by Geography:

The geographic scope of the gallium-68 market report entails North America (US, Canada, and Mexico), Europe (Spain, UK, Germany, France, Italy, and Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).  

In 2022, North America held the largest gallium-68 market share. Nuclear medicine in the US has grown significantly owing to advancements in technologies such as hybrid imaging, the introduction of novel radiopharmaceuticals for diagnosis and treatment, and the development of molecular imaging techniques based on the tracer principle. Access to advanced healthcare infrastructure, the rising incidence and prevalence of prostate cancer, and product innovations by key players further contribute to the expansion of the gallium-68 market in North America. According to the International Agency for Research on Cancer (IARC), the number of cancer cases in the US is expected to increase from 2.28 million cases in 2020 to 3.12 million cases by 2040. Thus, the increasing cancer cases are expected to boost demand for nuclear imaging, which favors the gallium-68 market progress.

Apart from factors driving the market, the gallium-68 market report emphasizes key developments by prominent players. Novartis AG, Telix Pharmaceuticals (US) Inc, IRE-ELiT SA, ITM Medical Isotopes GmbH, Eckert & Ziegler Radiopharma GmbH, ARTMS Inc, IBA Radiopharma Solutions, Cardinal Health, Rosatom, and Evergreen Theragnostics Inc are among the prominent players contributing to the gallium-68 market size. These companies have been implementing different strategies that contribute to their growth and lead to various changes in the market. Organic strategies implemented by them include product launches, expansions, and product approvals, while inorganic strategies include collaborations and partnerships.

• In December 2023, Ariceum Therapeutics was granted US and Canadian patents for its Gallium-68 (Ga-68) radiopharmaceutical production kit. The IP was developed by Theragnostics Ltd, which was acquired by Ariceum in 2023. Earlier, the production of Ga-68 radiopharmaceuticals involved a multistep approach, which limited the number of patient doses that could be produced at any time. The Ga-68 technology platform of Theragnostics enables the production of multiple doses of Ga-68 HBED-PSMA-11 in a single vial in one simple step.
• In March 2023, Telix Pharmaceuticals received FDA approval for its supplementary New Drug Application (sNDA) for Illuccix (Ga-68 gozetotide injection preparation kit) for the screening of patients with metastatic prostate cancer, who were recommended Lutetium-177 PSMA-directed therapy.

Contact Us
Contact Person: Content Team 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com